Cadila poised to join billion-dollar sales club in US by FY20

Cipla, Glenmark Pharma to catch up by FY21-22

For top Indian drug makers, the US market is the largest geography by sales, at 20-50 per cent of their consolidated revenues. Recently, Cadila Healthcare announced it was looking at doubling its sales over the next three years to reach the $1- billion mark in US sales from the current $553 million. Cadila has to grow this business at nearly 22 per cent annually to join the likes of Sun Pharmaceutical, Lupin, Dr Reddy’s and Aurobindo Pharma.

From 24 per cent of overall sales in FY15, the US accounted for 40 per cent of Cadila’s sales in FY17. Kunal Randeria